Evidence map›Paper›PMID 37662423›Full record

ArticlemedRxiv : the preprint server for health sciences2023

Persistent

Niveditha Ravindra, Laura W Dillon, Gege Gui, Matthew Smith, Lukasz P Gondek, Richard J Jones, Adam Corner, Christopher S Hourigan, Alexander J Ambinder

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Niveditha RavindraLaboratory of Myeloid Malignancies, Hematology Branch, National Heart Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Laura W DillonLaboratory of Myeloid Malignancies, Hematology Branch, National Heart Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Gege GuiLaboratory of Myeloid Malignancies, Hematology Branch, National Heart Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Matthew SmithSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD.
Lukasz P GondekSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD.
Richard J JonesSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD.
Adam CornerBio-Rad Laboratories, Digital Biology Group, 5731, W. Las Positias Blvd, Pleasanton, CA.
Christopher S HouriganLaboratory of Myeloid Malignancies, Hematology Branch, National Heart Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Alexander J AmbinderSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD.
Johns Hopkins University · USNational Institutes of Health · USBio-Rad (United States) · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI WILLIAM George NELSON · 1985 to 2026
$208.6M
Targeting MRDP01CA225618 · NCI · JOHNS HOPKINS UNIVERSITY · PI Catherine M. Bollard, KENNETH R COOKE · 2019 to 2026
$15.1M
NCI NIH HHS P01 CA225618NCI NIH HHS P30 CA006973
6 · The paper itself

Abstract

The presence of measurable residual disease (MRD) prior to an allogeneic hematopoietic transplant (alloHCT) in Acute Myeloid Leukemia (AML) has been shown to be associated with an increased risk of post-transplant relapse. Since the Isocitrate Dehydrogenase genes (

Identifiers

PMID37662423
PMCPMC10473775
OpenAlexW4386023398

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.